GlassScriptPhysician profile
Amanda Golden
NPI 1578214763
$6,235.37
in general payments reported to CMS, 2019-2025
48 companies · $2,216 in 2025
The $2,216 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $344 · 2023: $1,885 · 2024: $1,790 · 2025: $2,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,891.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,381.02 | 2023-2025 | |
| Lilly USA, LLC | $725.31 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Lundbeck LLC | $370.57 | 2022-2025 | Vyepti, Rexulti |
| Pfizer INC. | $336.90 | 2023-2025 | |
| Ucb, INC. | $332.56 | 2022-2025 | Rystiggo, Briviact, Zilbrysq |
| Eisai INC. | $319.40 | 2023-2025 | |
| Emd Serono, INC. | $205.89 | 2024-2025 | |
| Neurelis, INC. | $188.55 | 2022-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $180.27 | 2023-2025 | |
| Genentech USA, INC. | $153.33 | 2022-2025 | Ocrevus Zunovo |
| Jazz Pharmaceuticals INC. | $150.67 | 2022-2024 | |
| Inspire Medical Systems, INC. | $147.77 | 2023-2024 | Inspire |
| Harmony Biosciences LLC | $134.33 | 2023-2025 | Wakix |
| Alnylam Pharmaceuticals INC. | $126.92 | 2024-2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $126.10 | 2023 | Spravato |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $123.24 | 2023-2024 | Rytary, Ongentys 50mg Capsules 30 |
| Grifols USA, LLC | $99.32 | 2023-2025 | Gamunex-C |
| Argenx US, INC. | $87.76 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $79.27 | 2025 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $72.07 | 2022-2024 | Ponvory |
| Otsuka America Pharmaceutical, INC. | $59.29 | 2023-2025 | Rexulti |
| Springworks Therapeutics, INC. | $57.42 | 2025 | Gomekli |
| Csl Behring | $56.16 | 2023-2024 | Hizentra |
| Biogen, INC. | $55.38 | 2024-2025 | Vumerity, Tysabri |
| Merz Pharmaceuticals, LLC | $50.83 | 2024-2025 | Xeomin, Inbrija |
| Kyowa Kirin, INC. | $46.66 | 2022-2023 | Nourianz |
| Catalyst Pharmaceuticals, INC. | $44.15 | 2024 | |
| Kedrion Biopharma, INC. | $40.55 | 2025 | Koate, Albuked, Kedrab |
| Corium, LLC | $35.66 | 2023 | Adlarity |
| Alexion Pharmaceuticals, INC. | $35.57 | 2022-2023 | Soliris |
| Life Molecular Imaging LTD | $34.42 | 2025 | Neuraceq |
| Amgen INC. | $33.75 | 2024 | Uplizna |
| Axsome Therapeutics, INC. | $27.78 | 2025 | Symbravo |
| Ge Healthcare | $26.73 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.60 | 2023 | |
| Sk Life Science, INC. | $26.16 | 2023 | |
| Ani Pharmaceuticals, INC. | $25.49 | 2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $23.52 | 2025 | |
| Biotronik Nro, INC. | $21.87 | 2025 | Prospera |
| Nevro Corp. | $21.50 | 2024 | Senza |
| Acorda Therapeutics, INC | $20.83 | 2023 | Ampyra, Inbrija |
| Medtronic, INC. | $19.91 | 2023 | Intellis Adaptivestim |
| Insightec,INC | $19.69 | 2023 | Exablate |
| Nestle Healthcare Nutrition INC. | $19.64 | 2022 | |
| Cycle Pharmaceuticals INC | $18.48 | 2025 | Bafiertam, Tascenso Odt |
| Resmed Corp | $17.88 | 2023 | |
| Azurity Pharmaceuticals, INC. | $14.27 | 2023 | Horizant |
| Tg Therapeutics, INC. | $13.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Golden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.